MitoImmune Therapeutics

MitoImmune Therapeutics is a clinical-stage biopharmaceutical company based in Seoul, South Korea, focused on developing novel therapeutics targeting mitochondrial dysfunction and ferroptosis — a form of iron-dependent programmed cell death — in inflammatory and degenerative diseases. The company's proprietary MIT (Mitochondria-targeting Indole-based Therapeutics) Platform serves as the foundation for its lead compound MIT-001, which is in development for oral mucositis in head and neck cancer and blood cancer patients, graft-versus-host disease (GvHD), and neurodegenerative diseases including Alzheimer's disease. MitoImmune also pursues additional indications including Friedreich's Ataxia, leveraging two complementary delivery technologies: BIM (high blood-brain barrier penetration) and PIM (non-CNS targeting). The company is located in Songpa-gu, Seoul, within the Munjeong Hyundai Knowledge Industry Center.